anbefalede CHMP tilbagekaldelse af markedsføringstilladelserne for de i bilag I omhandlede lægemidler indeholdende veraliprid.
The CHMP has recommended the withdrawal of the Marketing Authorisations for the medicinal products containing veralipride referred to in Annex I.